Patents by Inventor Stefan HARTLE

Stefan HARTLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD38 ANTIBODIES FOR USE IN THE TREATMENT OF ANTIBODY-MEDIATED TRANSPLANT REJECTION
    Publication number: 20240132618
    Abstract: The present invention relates to the use of the anti-CD38 antibody felzartamab in the prophylaxis and/or treatment of antibody-mediated rejection (ABMR) of transplants. In accordance with the present invention, felzartamab is effective in the treatment of antibody-mediated renal allograft rejection.
    Type: Application
    Filed: March 1, 2022
    Publication date: April 25, 2024
    Inventors: Stefan Steidl, Stefan Härtle, Rainer Boxhammer
  • ANTI-CD38 ANTIBODIES AND THEIR USES
    Publication number: 20240109977
    Abstract: The present invention relates to the use of an anti-CD38 antibody or antibody fragment in the prophylaxis and/or treatment of diseases directly caused by immune complex deposits. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of IgA nephropathy (IgAN).
    Type: Application
    Filed: January 14, 2022
    Publication date: April 4, 2024
    Inventors: Stefan Steidl, Stefan Härtle, Rainer Boxhammer
  • Treatment Paradigm for an Anti-CD19 Antibody Therapy
    Publication number: 20230357392
    Abstract: The present disclosure provides anti-CD19 antibodies for use in the treatment of various cancers. The anti-CD19 antibody is administered to cancer patients in a specific dose or dosing regimen.
    Type: Application
    Filed: December 22, 2022
    Publication date: November 9, 2023
    Inventors: Stefan HÄRTLE, Frank STRIEBEL
  • CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA
    Publication number: 20230203189
    Abstract: Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the antibody in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
    Type: Application
    Filed: February 14, 2023
    Publication date: June 29, 2023
    Inventor: Stefan Härtle
  • Clinical assessment of M-protein response in multiple myeloma
    Patent number: 11618789
    Abstract: Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the anti-body in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 4, 2023
    Assignee: MORPHOSYS AG
    Inventor: Stefan Härtle
  • Treatment for multiple myeloma (MM)
    Patent number: 11591406
    Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: February 28, 2023
    Assignee: MORPHOSYS AG
    Inventors: Stéphane LeClair, Jan Endell, Stefan Härtle
  • ANTI-CD38 ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF AUTOANTIBODY-MEDIATED AUTOIMMUNE DISEASE
    Publication number: 20220144965
    Abstract: The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune disease. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of anti-PLA2R positive membranous glomerulonephropathy.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 12, 2022
    Inventors: Daniel KLUNKER, Rainer BOXHAMMER, Stefan HÄRTLE, Stefan STEIDL, Tiantom JARUTAT
  • TREATMENT FOR RHEUMATOID ARTHRITIS
    Publication number: 20210130451
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 6, 2021
    Applicant: MORPHOSYS AG
    Inventors: Stefan HARTLE, Stephane LECLAIR, Amgad SHEBL, Stefan STEIDL, Bodo BROCKS, Daniela Della DUCATA, Kai ROSPORT
  • Treatment for rheumatoid arthritis
    Patent number: 10913792
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 9, 2021
    Assignee: Morphosys AG
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
  • TREATMENT FOR MULTIPLE MYELOMA (MM)
    Publication number: 20200079871
    Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
    Type: Application
    Filed: November 25, 2019
    Publication date: March 12, 2020
    Inventors: Stéphane LeClair, Jan Endell, Stefan Härtle
  • Treatment for multiple myeloma (MM)
    Patent number: 10533057
    Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: January 14, 2020
    Assignee: MORPHOSYS AG
    Inventors: Stéphane LeClair, Jan Endell, Stefan Härtle
  • CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA
    Publication number: 20190077875
    Abstract: Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the anti-body in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
    Type: Application
    Filed: March 3, 2017
    Publication date: March 14, 2019
    Applicant: MORPHOSYS AG
    Inventor: Stefan Härtle
  • TREATMENT FOR MULTIPLE MYELOMA (MM)
    Publication number: 20190048091
    Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
    Type: Application
    Filed: May 13, 2016
    Publication date: February 14, 2019
    Inventors: Stéphane LeClair, Jan Endell, Stefan Härtle
  • TREATMENT FOR RHEUMATOID ARTHRITIS
    Publication number: 20180230208
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: January 26, 2018
    Publication date: August 16, 2018
    Applicant: Morphosys Ag
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl
  • TREATMENT FOR RHEUMATOID ARTHRITIS
    Publication number: 20150246969
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: September 19, 2013
    Publication date: September 3, 2015
    Applicant: MORPHOSYS AG
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl
  • Anti-IL12R?1 antibodies and their use in treating autoimmune and inflammatory disorders
    Patent number: 8999708
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: April 7, 2015
    Assignee: Novartis AG
    Inventors: Jose M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
  • Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
    Patent number: 8945548
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: February 3, 2015
    Assignee: Novartis AG
    Inventors: Jose M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
  • Anti-IL12Rbeta1 Antibodies And Their Use In Treating Autoimmune And Inflammatory Disorders
    Publication number: 20140120101
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 1, 2014
    Applicant: NOVARTIS AG
    Inventors: Jose M. CARBALLIDO HERRERA, Stefan HARTLE, Christoph HEUSSER, Ingo KLAGGE, Andrea POLZER, Christoph SCHWAERZLER, Gabriela WOCHNIK-VELTRUP
  • Anti-IL12Rbeta1 Antibodies And Their Use In Treating Autoimmune And Inflammatory Disorders
    Publication number: 20140099708
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Application
    Filed: October 3, 2013
    Publication date: April 10, 2014
    Applicant: NOVARTIS AG
    Inventors: Jose M. CARBALLIDO HERRERA, Stefan HARTLE, Christoph HEUSSER, Ingo KLAGGE, Andrea POLZER, Christoph SCHWAERZLER, Gabriela WOCHNIK-VELTRUP
  • Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
    Patent number: 8574573
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: November 5, 2013
    Assignee: Novartis AG
    Inventors: José M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup